Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality

European Urology

Volumn 64, Issue 3, 2013, Pages 384-393

  Ørsted, David D ^a,b   Bojesen, Stig E ^a,b,c   Kamstrup, Pia R ^a   Nordestgaard, Børge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Long term PSA velocity; Prostate cancer incidence and mortality; Risk classification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RISK; CONTROLLED STUDY; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY;

LONG-TERM PSA VELOCITY; PROSTATE CANCER INCIDENCE AND MORTALITY; RISK CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84881149119     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.01.028     Document Type: Article

References (35)

1. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436
2. D.D. Ørsted, B.G. Nordestgaard, G.B. Jensen, P. Schnohr, and S.E. Bojesen Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population Eur Urol 61 2012 865 874
3. S.P. Balk, Y.J. Ko, and G.J. Bubley Biology of prostate-specific antigen J Clin Oncol 21 2003 383 391
4. H.B. Carter, J.D. Pearson, and E.J. Metter Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267 1992 2215 2220
5. A.S. Whittemore, C. Lele, and G.D. Friedman Prostate-specific antigen as predictor of prostate cancer in black men and white men J Natl Cancer Inst 87 1995 354 360
6. Prostate-specific Antigen Best Practice Statement Update Panel Members. Prostate-specific antigen best practice statement. American Urological Association Web site. http://www.auanet.org/content/media/psa09.pdf.
7. Prostate cancer detection v.1.2007. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician-gls/pdf/prostate- detection.pdf.
8. A.V. D'Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy N Engl J Med 351 2004 125 135
9. S.E. Eggener, K.A. Roehl, O. Yossepowitch, and W.J. Catalona Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy J Urol 176 2006 1399 1403
10. S.E. Eggener, O. Yossepowitch, and K.A. Roehl Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program Urology 71 2008 1016 1019
11. A.J. Vickers, C. Till, C.M. Tangen, H. Lilja, and I.M. Thompson An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 462 469
12. X. Yu, M. Han, and S. Loeb Comparison of methods for calculating prostate specific antigen velocity J Urol 176 2006 2427 2431
13. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
14. M.F. O'Brien, A.M. Cronin, and P.A. Fearn Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy J Clin Oncol 27 2009 3591 3597
15. H.B. Carter, L. Ferrucci, and A. Kettermann Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability J Natl Cancer Inst 98 2006 1521 1527
16. S. Loeb, H.B. Carter, and E.M. Schaeffer Distribution of PSA velocity by total PSA levels: Data from the Baltimore Longitudinal Study of Aging Urology 77 2011 143 147
17. D. Ulmert, A.M. Serio, and M.F. O'Brien Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population J Clin Oncol 26 2008 835 841
18. B.A. Inman, J. Zhang, N.D. Shah, and B.T. Denton An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time BJU Int 110 2012 375 381
19. S. Loeb, A. Kettermann, L. Ferrucci, P. Landis, E.J. Metter, and H.B. Carter PSA doubling time versus PSA velocity to predict high-risk prostate cancer: Data from the Baltimore Longitudinal Study of Aging Eur Urol 54 2008 1073 1080
20. S. Loeb, E.J. Metter, D. Kan, K.A. Roehl, and W.J. Catalona Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer BJU Int 109 2012 508 513
21. A.J. Vickers, C. Savage, M.F. O'Brien, and H. Lilja Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer J Clin Oncol 27 2009 398 403
22. K.H. Allin, S.E. Bojesen, and B.G. Nordestgaard Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer J Clin Oncol 27 2009 2217 2224
23. S.E. Bojesen, A. Tybjærg-Hansen, and B.G. Nordestgaard Integrin beta3 Leu33Pro homozygosity and risk of cancer J Natl Cancer Inst 95 2003 1150 1157
24. D.D. Orsted, S.E. Bojesen, A. Tybjærg-Hansen, and B.G. Nordestgaard Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population J Exp Med 204 2007 1295 1301
25. J. Zacho, A. Tybjærg-Hansen, and J.S. Jensen Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 2008 1897 1908
26. A.J. Vickers Re: An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection J Natl Cancer Inst 103 2011 1635 1636
27. M.J. Pencina, R.B. D'Agostino, K.M. Pencina, A.C. Janssens, and P. Greenland Interpreting incremental value of markers added to risk prediction models Am J Epidemiol 176 2012 473 481
28. D.D. Ørsted, S.E. Bojesen, S.F. Nielsen, and B.G. Nordestgaard Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: A nationwide cohort study of 3 009 258 men Eur Urol 60 2011 691 698
29. T.O. Mukai, F. Bro, K.V. Pedersen, and P. Vedsted Use of prostate-specific antigen testing [in Danish] Ugeskr Laeger 172 2010 696 700
30. S. Loeb, K.A. Roehl, B.T. Helfand, D. Kan, and W.J. Catalona Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol 183 2010 112 116
31. S.E. Eggener, K.A. Roehl, and W.J. Catalona Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy J Urol 174 2005 500 504
32. J. Fang, E.J. Metter, P. Landis, and H.B. Carter PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml Urology 59 2002 889 893
33. S. Loeb, D.E. Sutherland, A.V. D'Amico, K.A. Roehl, and W.J. Catalona PSA velocity is associated with gleason score in radical prostatectomy specimen: Marker for prostate cancer aggressiveness Urology 72 2008 1116 1120
34. D.D. Ørsted, B.G. Nordestgaard, G.B. Jensen, P. Schnohr, and S.E. Bojesen Reply from authors re: Stacy Loeb. Use of baseline prostate-specific antigen measurements to personalize prostate cancer. Eur Urol 2012;61:875-6 Eur Urol 61 2012 876 877
35. H.B. Carter, A. Kettermann, L. Ferrucci, P. Landis, and E.J. Metter Prostate-specific antigen velocity risk count assessment: A new concept for detection of life-threatening prostate cancer during window of curability Urology 70 2007 685 690